Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021

October 7, 2021

Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its ‘Psybrary’ of Psychedelic Molecular Compounds

October 5, 2021

Enveric Biosciences to Participate in Upcoming Investor Conferences in September 2021

September 20, 2021

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

September 17, 2021

Enveric Biosciences Announces MagicMed Industries’ Presentations at the Following Investor Conferences in September

September 9, 2021

Enveric Biosciences CEO, David Johnson, Issues Letter to Shareholders

August 18, 2021

Enveric Biosciences Announces Approval from Israel’s Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma

July 8, 2021

Enveric Biosciences and MagicMed to Participate in June 2021 Investor and Industry Conferences

June 3, 2021

Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives

May 24, 2021

Enveric Biosciences Reports First Quarter 2021 Financial Results

May 18, 2021

‹
1
…
9
10
11
12
13
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2024 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.